Touching reminder of the loved ones who are so deeply affected by COVID19. – at Texas, USA
A heartwarming welcome in the hospital hall with the supportive drawings sent by the children of our patients @HopSaintLouis @APHP
#MPNandCOVID19
Hello to everyone on today's very timely twitter chat! I hope this finds you all very well! I am Dr. Robyn Scherber, MPN specialist at UT Health San Antonio MD Anderson Cancer Center. Please feel free to post your questions, concerns and thoughts here!
Robyn M. Scherber MD retweeted
Our very own Dr. Scherber! @RobynScherber @UTHealthSAMDA @UTHealthSA
Watch a video of Dr Robyn Scherber discussing the extent of the symptom burden in patients with polycythemia vera (PV). #MPNSM
Robyn M. Scherber MD retweeted
Honored to join @andrewschorr and @RobynScherber in @PatientPower for a discussion on What Are the COVID-19 Risks for MPN Patients? | Patient Power @UTHealthSAMDA patientpower.info/myeloproli…
So proud of my previous co-fellow Dr Shatzel and his critical work to move the field of thrombosis! ncbi.nlm.nih.gov/m/pubmed/30…… @Clotmaster
Impactful presentations this weekend at the Mayo AZ Heme/Onc review. Therapies continue to expand at unprecedented rates! @az_onc
Donated blood yesterday, and ironically ended up making the nightly San Antonio news! kens5.com/mobile/article/new…
Amazing to spend time with the @PatientPower team at ASH 2019 talking about new therapies in blood cancers patientpower.info/navigating…
Robyn M. Scherber MD retweeted
Thanks for a great interview @mpdrc. Brilliant updates on #Myelofibrosis!
@UTHealthSAMDA @ASH_hematology @VJHemOnc #MPNsm #CTSM #TrialUpdate #ASH19
Want to change the future of MPN care? Encourage patients to sign up for the MPN registry! Www.Mympn.org @MPN_RF @myMPNLindsey
Not only upping our anemia options in MF, but setting the higher bar in terms of ASH fashion. Bravo! @ASH_hematology
Robyn M. Scherber MD retweeted
Replying to @AaronGerds @doctorpemm
Exciting new therapies in MPNs @ASH_hematology : ropeginterferon, metformin, LCL161, luspatercept, LSD1 inhibition, SL401.
Congratulations to the new MPN Research Foundation challenge grantees! Exciting new projects in the works!
New exciting research for MPN patients in the works! Amazed by the intense productivity and dedication of the MRF team.
Robyn M. Scherber MD retweeted
#ASH19 |Dr Montalban-Bravo & @garciamanero |Long-Term Follow up Randomized Ph2 Low-Dose Decitabine Vs Low-Dose Azacitidine patients w/Lower-Risk MDS | n=113; med age 70;med#cy=15. Low-dose HMA Safe/can improve outcomes in lower-risk MDS | #MDSsm ash.confex.com/ash/2019/webp…




















